In Vitro Verification of Shape Memory Polymer Vascular Occlusion Plug by Diguette, Katelin
 
 
IN VITRO VERIFICATION OF SHAPE MEMORY POLYMER 
VASCULAR OCCLUSION PLUG 
 
 
An Undergraduate Research Scholars Thesis 
by 
KATELIN DIGUETTE 
 
 
Submitted to the Undergraduate Research Scholars program  
Texas A&M University 
in partial fulfillment of the requirements for the designation as an 
 
 
UNDERGRADUATE RESEARCH SCHOLAR 
 
 
Approved by 
Research Advisor:         Dr. Duncan Maitland 
 
 
May 2016 
 
 
Major: Biomedical Engineering 
 
 
TABLE OF CONTENTS 
Page 
ABSTRACT ............................................................................................................................ 1 
CHAPTER  
 I INTRODUCTION ............................................................................................ 2 
            Clinical need ..................................................................................................... 2 
            Current treatments ............................................................................................. 2 
            Previous research .............................................................................................. 4 
            Background on proposed research ..................................................................... 6 
            Research objectives ........................................................................................... 7 
 
 II METHODS ....................................................................................................... 8 
 
            Device migration ............................................................................................... 8 
           Working time .................................................................................................. 10           
 Device friction ................................................................................................ 10 
            Particulate generation ...................................................................................... 11 
 
 III RESULTS ....................................................................................................... 13 
            Device migration ............................................................................................. 13 
            Working time .................................................................................................. 14 
            Device friction ................................................................................................ 15 
            Particulate generation ...................................................................................... 16 
 
 IV CONCLUSION ............................................................................................... 18 
 
REFERENCES ...................................................................................................................... 19 
CONTACT INFORMATION ................................................................................................ 21 
1 
 
ABSTRACT 
In Vitro Verification of a Shape Memory Polymer Vascular Occlusion Device 
 
Katelin Diguette 
Department of Biomedical Engineering 
Texas A&M University 
 
Research Advisor: Dr. Duncan Maitland 
Department of Biomedical Engineering 
 
The objectives for the current in vitro experiments are to perform verification tests that 
demonstrate the safety and feasibility of a proposed vascular occlusion plugs (VOPs) and the 
validity of the device design criteria. Tests will be executed to monitor the following qualities: 
migration, working time, device friction, and particulate generation.  Results from device testing 
provides positive conclusions regarding the feasibility of the VOP design for peripheral 
embolization. There was limited risk of unintended embolization due to device migration. 
Expansion rates provide sufficient time for a physician to deliver the device trough a standard 
catheter. Frictional forces during expansion in catheter do not prevent delivery. Devices do not 
fracture or generate particulates that may cause thromboembolisms. All of the measured 
characteristics will aid in the design and optimization of novel SMP-based peripheral 
embolization devices. 
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CHAPTER I 
INTRODUCTION 
 
Clinical need 
Blood is moved from the leg toward the heart predominantly by the propelling action of the leg 
muscles. As blood moves from the deep to the superficial system via muscular contractions, the 
superficial venous pressure increases. [1] Pelvic congestion syndrome (PCS) occurs when 
hypertension and elevated venous pressure cause valve incompetence in the ovarian veins. 
Venous blood flow then deviates from its normal path and forces flow in a retrograde direction 
so that fluid accumulates and causes bulging varicose veins. [1-3] Lower extremity venous 
insufficiency affects approximately 25% of women and 15% of men. [4] PCS manifests itself as 
chronic pelvic pain in as high as 39.1% of premenopausal women worldwide and accounts for 10 
to 15% of outpatient gynecologic visits in the United States. [5] In fact, it is estimated that 6 
million people in the US suffer from severe symptoms of chronic venous insufficiency such as 
pain, varicose veins, edema, and venous stasis ulcers. [6]  
 
Current treatments 
Treatments for venous insufficiency aim to block or divert blood flow to a specific region of the 
body. The most common region for treating lower limb venous insufficiency is within the great 
saphenous vein (GSV) (Figure 1). [8] There are four treatment modalities most often used to 
treat varicosities: surgical ligation, sclerotherapy, endovenous ablation, and implantation of 
embolic devices.  
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Figure 1. Schematic of lower limb veins. [7] 
 
GSV incompetency is conventionally treated with ligation and stripping at the saphenofemoral 
junction. The treatment is effective with low recurrence rates. It is also more cost effective than 
endovenous ablation. [9] However, it is a surgical procedure with multiple negative effects 
including: requires general anesthesia, increased risk of infection, excessive nerve damage, and 
scarring or bruising with postoperative pain. [9, 8] Additionally, recurrence of incompetency 
occurs in up to two-thirds of patients after five years. [10] Sclerotherapy involves injecting a 
chemical solution directly into the vein. The liquid sclerosant chemically burns the endothelium 
causing the vessel walls to spasm and stick together. [11] This process ultimately causes blood to 
clot. Sclerotherapy can be used to treat short tortuous vessels and does not require anesthesia; [9] 
however, it is difficult to compress the ablated vein in the pelvic region. [11] Because this 
method uses a chemical solution, there are potential consequences of the chemical flowing 
downstream in the vessel. Other negative indications include recanalization, recurrence, 
thrombophlebitis, skin pigmentation, and tissue necrosis. [9] Endovenous laser ablation, or 
cauterization to close the veins, requires the use of detailed imaging and advanced understanding 
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of the anatomy of lower extremity veins. This procedure has low recurrence rates, is minimally 
invasive, and has rapid recovery. [9] If precision is lacking, laser energy can damage small 
arterial branches around the vein in patients and cause severe peripheral artery disease. 
Complications include bruising, soreness, tenderness, and indurations along the treated vein 
segment. [8] The fourth treatment modality is permanently implanted embolic devices made up 
of platinum coils. [11] Coils are delivered through a micro catheter to block flow in the desired 
vein with a cluster of material. Platinum coils have high flexibility and good for visualization 
under fluoroscopy. [11] There is poor tissue healing and high recurrence from these metallic 
implants. The proposed shape memory polymer foams provide what many of these treatments 
lack: rapid occlusion. Foams are porous materials that provide high surface area for high volume 
occlusion. There exists a clinical need for a vascular plug to achieve faster occlusion than current 
platinum coils to treat lower extremity venous insufficiency.  
 
Previous research 
The focus of this research is to characterize the behavior of thermally actuated, amorphous, 
covalently crosslinked shape memory polymer (SMP) foams. SMP foams are soft, compliant 
materials that can be fabricated into essentially any shape. Their initial geometry can then be 
deformed by raising the temperature of the material above its glass transition temperature and 
applying a force. While the force is still applied, the foam can be cooled below its transition 
temperature to program the material into a temporary, secondary shape. The SMP foam will 
remain in its secondary shape until it is reheated above its transition temperature (Figure 2). [12] 
This shape memory property makes these materials optimal for minimally invasive endovascular 
interventions, as a compressed foam can be delivered via catheter and then expand to fill the 
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vessel upon heating to body temperature. This work focuses on the application of SMP foams for 
endovascular intervention in lower extremity venous insufficiency.   
 
 
Figure 2. Shape memory polymer, a) Original shape b) temporary shape, and c) thermo-
responsive shape recovery.  
 
In a previous porcine study, a SMP foam was implanted in an aneurysm in the right carotid 
artery for up to 90 days. Scanning electron microscopy (SEM) images of the explanted sample 
showed that there was complete covering of the exposed foam with endothelial cells aligned 
parallel to the arterial blood flow, the surface exhibited a lack of mural thrombi, and the 
aneurysm was completely healed. Histology of the aneurysm revealed an increase in connective 
tissue and decreased swelling after treatment with the SMP foam. [12] In another in vivo vascular 
occlusion study, foams deployed into porcine hind limbs occluded within 90 to 128 seconds. [13] 
Thus, benefits of this treatment include rapid thrombus formation, high material compliance to 
accommodate collagen contraction and lesion shrinkage, and tissue scaffold-like behavior 
allowing for rapid cellular infiltration and stable long-term healing with minimal inflammation.  
Desired outcomes such as these may allow for reduced procedural and recovery times for the 
patient, as well as a reduced likelihood of recurrence.  
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Background on proposed research 
A polyurethane SMP foam embolization device has been investigated for vascular occlusion. 
The vascular occlusion plug (VOP) is fabricated as a cylinder 10 or 20 mm in length and 8 mm 
in diameter (Figure 3). The SMP foam component can be categorized into two main groups 
based on device stiffness or pore size. Crosslink density, which affects the transition temperature, 
is controlled by altering the polyol component of the polyurethane and is divided into three 
different types: H40, H50, and H60, based on increasing the concentration of N,N,N′,N′-
tetrakis(2-hydroxypropyl)ethylenediamine (HPED, H)). Thus, H60 has the highest crosslink 
density of the tested formulations and the longest expansion time.  
 
The pore size is also broken down into three main types: small (500 μm), medium (1000 μm), 
and large (1500 μm). For this study, only large pore devices were analyzed. Upon contact with 
circulating blood, the foam diameter undergoes up to 8X expansion to effectively occlude large 
peripheral vessels with a single device. Based on the efficacy of the SMP foam for aneurysm 
treatment, it is hypothesized that it will perform in a similar manner for this application in the 
peripheral vasculature.  To utilize these foams as VOPs, verification of safety and feasibility of 
use is required.  
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Figure 3. Vascular occlusion plug design. Each device is crimped to approximately 1 mm in 
diameter for non-invasive delivery through a catheter. The vascular plug design contains a distal 
platinum coil that anchors inside the vessel while the foam expands. Each device was made with 
3 coil revolutions.  
 
Research objectives 
The objectives for current in vitro experiments are to perform verification tests that demonstrate 
(i) the safety and feasibility of the proposed VOPs and (ii) the validity of the device design 
criteria. Tests will be executed to monitor the following qualities: migration, working time, 
device friction, and particulate generation.   
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CHAPTER II 
METHODS 
 
Device migration  
To ensure the SMP foam is retained within the treatment region, the VOPs are tested in a thin-
walled silicone model of a human GSV maintained at 37°C under varying flow rates. To 
fabricate the silicone model, a tapered mold was machined out of Delrin® that is 6 cm in length. 
The model, made of Sylgard®, has a wall thickness of approximately 600 μm and tapers outward 
to mimic the physiology of the GSV (Figure 4). The lumen of the model tapers from an inner 
diameter of 5.8 mm up to 6.8 mm over the 6 cm length to cover a majority of the diameters seen 
in the thigh region of the GSV in vivo. The taper of the model is more than three times of that 
typically seen clinically to provide a rigorous model for testing device stability [14].  
 
 
Figure 4. Tapered GSV lumen model. Thin-walled silicone model diameter tapers from 5.8 mm 
up to 6.8 mm over the length of 6 mm to represent the GSV diameters found in vivo. Direction 
of flow is indicated by the arrow. 
 
9 
 
To test the stability of the VOP, the devices (1 cm length) are delivered through a 5F catheter 
into a flow loop (Figure 5) and deployed through the catheter at the small end of the GSV model 
lumen. Each device is given time to fully expand under an initial flow rate of 40 mL/min, four 
times the GSV flow rate typically seen in vivo (10 mL/min). [15] The pump is then increased by 
50 ml/min every minute until the device is seen to move. The device was tested until the 
peristaltic pump maxed out its capacity at 1000 ml/min. The last flow rate at which the device 
did not move more than 2 mm over a 1 minute time interval is recorded as the maximum flow 
rate of the device. A digital camera (Canon Power Shot SX230) is positioned over the lumen to 
capture an image for each time interval. Taking the average of 5 devices for each foam 
composition (H40, H50, and H60), the highest flow rate in which the device did not migrate was 
recorded. Images captured with the digital camera are used to monitor device migration.  
 
 
Figure 5. Schematic representation of the flow system components and flow directions. 
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Working time  
Working time is defined as the time from when the device is first introduced into the catheter and 
the time at which the device can no longer be advanced through the catheter due to excessive 
foam expansion. Too short of a working time will prevent the device from being delivered 
through the catheter, and too long of a working time may result in excessive waiting times for the 
physician to verify total vessel occlusion, resulting in customer dissatisfaction and prolonged 
procedural times. To perform working time studies, a water bath equilibrated at 37°C is 
implemented such that the devices under investigation can be monitored without any radial 
restrictions. A stopwatch is used to monitor the time between device introduction into the water 
bath and the time at which the device reaches its original shape. Images of the device are taken 
using the digital camera at 30 second intervals for up to 15 minutes. ImageJ software (NIH, 
Bethesda, MD) is used to analyze the foam diameter at each time interval. Taking the original 
diameter, the percentage of original shape recovered over time is calculated. The average results 
of 5 devices for each foam composition (H40, H50, and H60) were then reported.  
 
Device friction 
The frictional force of the device retraction through the catheter is monitored to provide a 
measure of friction between the device and catheter walls as a function of time. For the device 
friction studies, a three-foot long piece of 0.010” diameter nitinol wire is glued to the proximal 
end of the VOPs. The devices are then introduced into the flow system shown in Figure 5, and 
the nitinol wire is attached to a MTS single-column tensile testing machine (Insight 30 Material 
Tester) to measure frictional force as the devices are retracted. Device retraction occurs at a rate 
of 50.8 mm/min through the catheter while the flow system flushes 37°C water through the GSV 
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model lumen at 40 ml/min. [15] A current clinical vascular occlusion device, the Amplatzer 
Vascular Plug (AVP, St. Jude Medical), is used for comparison of frictional forces. [16] 
 
Particulate generation  
Verification of the amount of particulate generation is used to ensure that the foam does not 
fracture or release particulates that could potentially cause emboli downstream from the device. 
After the flow system is equilibrated at 37°C, the VOP is crimped and loaded into a 5F catheter 
that is navigated to the middle of the GSV model lumen. A guidewire holds the VOP into the 
desired location of the lumen. The foam is instantly exposed to water to induce actuation. Using 
a peristaltic pump, the flow rate through the model lumen is increased to a maximum flow rate of 
40 mL/min [15], providing a rigorous in vitro test for the VOP. A baseline particulate 
measurement is taken with just the catheter and guidewire in the model lumen prior to 
introducing the foam. Then, a sample is taken while the foam is in the catheter but not yet 
deployed. The final sample is obtained after the foam is deployed from the catheter. The outlet of 
the GSV model lumen is drained to capture all particulates and fluid that are flushed through the 
device.  
 
The contents of each collection basin are then placed in a Chemtrac PC5000 (Chemtrac, 
Norcross, GA) particle counter. The particle counter outputs raw counts of the total number and 
size of particulates generated during each run. Particle counts from the SMP foams are then 
compared to the limits for small volume infusions stated in United States Pharmacopeia (USP) 
standard number 788 (Table 1) to characterize the foams on the basis of particulate generation. 
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Particulate data is collected for two distinct size ranges: > 10 μm and > 25 μm, as recommended 
by USP 788. 
 
Table 1. USP 788 Acceptable limits for injection of parenteral infusion. [17] 
Volume Particle Size Limit Acceptable Number of Particulates 
>100 ml >10 μm 25/ml 
>100 ml >25 μm 3/ml 
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CHAPTER III 
RESULTS 
 
Device migration  
Each H40, H50, and H60 device was deployed through a 5F catheter with the coil entering the 
small end of the GSV model lumen first. Taking the average of 5 devices for each foam 
composition, the highest flow rate in which the device did not migrate was recorded. Results 
show that the devices remained stable up to 90 times the average GSVflow rate of 10 ml/min 
[15] (Figure 6).  
 
 
Figure 6. Flow rate at which devices migrated at least 2 mm in 1 minute. Dashed line indicate 
average flow rate in GSV.  
 
When comparing the three foam compositions, the formulations produced similar results. In the 
final device design, the distal platinum coil serves as an anchor for the device. The coil 
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revolutions have a larger radius than the foam and provides a stronger radial force than the foam. 
Thus, the foam composition did not have as large of an effect on device migration as the size of 
the coil revolutions. Future studies could be done to observe how the coil diameter and number 
of revolutions effect migration.      
 
Working time 
A study was carried out to analyze the effects of crosslink density (HPED (H) concentration) on 
working time. Figure 7 shows the percent shape recovery over time after submersion with H40, 
H50, and H60 large pore foams. 
 
 
Figure 7. Shape recovery of large pore foams with varied amounts of HPED. 
 
All formulations experience 100% shape recovery after 10 minutes. H60 has the highest 
crosslink density, resulting in a higher glass transition temperature than that of H50 and H40 
foams, which results in slower water plasticization and subsequent expansion. Therefore, H60 
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experiences the slowest rate of expansion after submersion. In contrast, H40 has the fastest 
expansion rate due to its reduced crosslink density. This data provides a baseline for 
understanding how much time a physician has to place the device before complete expansion. 
Combining these results with device friction measurements, we can quantify the time that a 
physician has before the radial force from the foam on the catheter is too great to continue the 
procedure.  
  
Device friction 
Device friction can be directly correlated to working time. Hypotheses can be drawn from the 
trends of large pore foam-based devices and applied to other pore sizes based on the correlation 
between device friction and working time. As shown in Figure 8, the H40 foam formulation 
experiences a peak force between 2-4 minutes, while the H60 foams have a peak force at 8 
minutes. This result is due to the slower expansion rate with increased HPED content and 
correlates with the working time study results.  
 
 
Figure 8. Device friction for H40, H50, and H60 foam compositions, measured using the MTS. Dashed 
line indicates the friction force of the commercially available AVP device.  
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After complete expansion, all devices require less than 2.10 N of force to pull through a catheter. 
This result indicates that a physician only requires 2.10 N to deploy the device regardless of how 
long the device remains inside the catheter. As a comparison, the AVP, a current device used for 
a similar application, underwent the same testing procedure. The 14 mm AVP device was used in 
an 8F catheter, as recommended by the supplier, and pulled for 1 minute. There is not a shape 
memory element to the AVP device, and radial force is therefore constant throughout. The test 
results in a force of 1.12 N. (Figure 8) Based on this information, the H40 formulation provides 
almost twice the delivery resistance as its competitors. H50 and H60 formulations reach 
maximum forces at 4 and 8 minutes, respectively. H50 produces the lowest maximum force at 
1.58 N within the desired window. H60 reaches its peak several minutes beyond the maximum 
desired window of time. This result indicates a delayed expansion which would extend the time 
to complete the procedure. Based on discussion with clinicians, the target working time for this 
device is 3-5 minutes. The results from this study indicate that the SMP foam-based VOPs could 
be successfully delivered in this time frame without getting stuck in the catheter.  
 
Particulate generation 
This test is employed to identify worst case scenarios for particulate generation; thus, 2 cm long 
foams were used to collect particulates. The particulates generated during deployment for each 
type of foam was recorded. Data collected when the foam was not in the flow loop is used as a 
baseline to which the data was normalized (Figure 9). There are minimal particulates generated 
while the device is still within the catheter (data not shown). While the device is still tightly 
crimped, it is unlikely to produce particulates. Most of the particulates were counted after the 
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device was deployed. The data suggests that the act of pushing the foam out of the catheter 
generates the majority of the particulates.  
 
 
Figure 9. Particulate counts per mL after deployment. Results were normalized with baseline 
particle counts. Solid line indicates acceptance criterial for particles greater than 10 μm. Dashed 
line indicates acceptance criteria for particles greater than 25 μm.  
 
The number of particles greater than 10 μm were less than 25 per milliliter, and the number of 
particles greater than 25 μm were less than 3 per milliliter for all foam formulations. Between the 
three formulations, H60 produced the lowest amount of particulates. This result could be due to 
its increased stiffness while in the catheter before the polymer is completely plasticized by the 
water within the flow loop.   
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CHAPTER IV 
CONCLUSION 
 
This study expanded on the verification of a previously proposed peripheral embolization design 
by quantifying the stability, working time, device friction, and particulate generation of the large 
pore device formulation. These devices show promise in peripheral applications requiring 
increased stability in rapid flowing vessels. The excellent shape memory properties of these 
materials allows the device to be deployed in minutes. The unconstrained working time results 
give a baseline for understanding the expansion rate of different foam formulations to enable 
rational design of a foam formulation to achieve desired working times.  
 
Device friction provides data that is relevant to clinical implementation of the device design and 
verifies the necessary working time. This information will provide physicians accurate 
information regarding the time frame in which they have to place the device in the desired 
location before complete expansion occurs. To conform to health and safety standards of an 
implantable product, particulate generation must be monitored. Knowing which formulations 
produce higher particulates is necessary for future product approval and making informed 
decisions of appropriate foam formulations. All of the measured characteristics will aid in the 
design and optimization of novel SMP-based peripheral embolization devices.  
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